Professor, Internal Medicine, UC, Davis School of Medicine
Cardiology
Dr. Amparo C. Villablanca, MD
|
|
Give Review
Doctor Amparo C. Villablanca, MD is an expert in the field of Cardiology. She went to medical school at University of California Davis School of Medicine. University of California Davis School of Medicine has a rank of 43 in research and a 19 in primary care She over the years received 3 awards: "Regional Top Doctor", "CMS Meaningful Use Stage 1 Certification" and "Super Doctor". Amparo Villablanca is also a published MD. She has 39 publication published. The most recent publication is: Heart disease during pregnancy. Which cardiovascular changes reflect disease? Amparo C. Villablanca is registered with Medicare and accepts Medicare payments.
Publications
- Gender differences in experiences of k-awardees: beyond space, resources and science.
- The Women in Medicine and Health Science Program: An Innovative Initiative to Support Female Faculty at the University of California Davis School of Medicine.
- Community-Based Cardiovascular Disease Prevention to Reduce Cardiometabolic Risk in Latina Women: A Pilot Program.
- Testosterone-derived estradiol production by male endothelium is robust and dependent on p450 aromatase via estrogen receptor alpha.
- Improving Knowledge, Awareness, and Use of Flexible Career Policies Through an Accelerator Intervention at the University of California, Davis, School of Medicine.
- Murine Cytomegalovirus (MCMV) Infection Upregulates P38 MAP kinase in Aortas of Apo E KO Mice: a Molecular Mechanism for MCMV-Induced Acceleration of Atherosclerosis.
- Generational and gender perspectives on career flexibility: ensuring the faculty workforce of the future.
- Attitudes, Awareness, and Use of Family-Friendly Policies for Career Flexibility: An NIH ORWH-Funded Study to Enhance Women's Careers in Biomedical Sciences.
- The Office on Women's Health Initiative to Improve Women's Heart Health: Focus on Knowledge and Awareness Among Women with Cardiometabolic Risk Factors.
- Maternal and neonatal exposure to environmental tobacco smoke targets pro-inflammatory genes in neonatal arteries.
- Outcomes of comprehensive Heart care programs in high-risk women.
- The Office on Women's Health initiative to improve women's Heart health: program description, site characteristics, and lessons learned.
- Postprandial metabolic responses to dietary glycemic index in hypercholesterolemic postmenopausal women.
- 17beta-estradiol prevents early-stage atherosclerosis in estrogen receptor-alpha deficient female mice.
- Outcomes of national community organization cardiovascular prevention programs for high-risk women.
- Compromised aortic vasoreactivity in male estrogen receptor-alpha-deficient mice during Acute lipopolysaccharide-induced inflammation.
- Hyperglycemia and loss of ovarian hormones mediate atheroma formation through endothelial layer disruption and increased permeability.
- Chronic consumption of flavanol-rich cocoa improves endothelial function and decreases vascular cell adhesion molecule in hypercholesterolemic postmenopausal women.
- Cardiovascular actions of selective estrogen receptor modulators and phytoestrogens.
- Soy protein with isoflavones has favorable effects on endothelial function that are independent of lipid and antioxidant effects in healthy postmenopausal women.
- Differential regulation of gene expression by ovariectomy in mouse aorta.
- Time- and dose-dependent differential upregulation of three genes by 17 beta-estradiol in endothelial cells.
- Estrogens and lipids. Can HRT designer estrogens, and phytoestrogens reduce cardiovascular risk markers after menopause?
- Atherosclerosis and sex hormones: current concepts.
- This issue includes more than a conventional discussion of Heart disease in women.
- Susceptibility to early atherosclerosis in male mice is mediated by estrogen receptor alpha.
- Nicotine stimulates DNA synthesis and proliferation in vascular endothelial cells in vitro.
- Coronary Heart disease in women. Gender differences and effects of menopause.
- 17beta-estradiol stimulates substance P receptor gene expression.
- Smoking and cardiovascular Disease.
- Heart disease during pregnancy. Which cardiovascular changes are normal or transient?
- Heart disease during pregnancy. Which cardiovascular changes reflect disease?
- Substance P increases microvascular permeability via nitric oxide-mediated convective pathways.
- Bronchial vasodilation by histamine in sheep: characterization of receptor subtype.
- Growth-promoting effects of substance P on endothelial cells in vitro. Synergism with calcitonin gene-related peptide, insulin, and plasma factors.
- Substance P stimulates vascular endothelial cellular reducing capacity in the presence of insulin and human plasma factors.
- Mutation analysis of MEN1, HRPT2, CASR, CDKN1B, and AIP genes in Primary hyperparathyroidism patients with features of genetic predisposition.
- Inflammation and Cardiometabolic Risk in African American Women Is Reduced by a Pilot Community-Based Educational Intervention.
Schools
University Of California Davis School Of Medicine
UC Davis
Procedures Preformed
- Ablation for Treatment of Cardiac Arrhythmias
- Cardiac Catheterization (incl. Coronary Angiography)
- Cardiac Imaging
- Cardiac Myocardial Perfusion Imaging
- View All
Conditions Treated
- Aneurysm and Dissection of Heart
- Angina and Acute Coronary Syndrome
- Aortic Aneurysm
- Aortic Valve Disease
- View All
Doctors Specialties
- Cardiology
Accepted Insurances
Awards
- Regional Top Doctor
- CMS Meaningful Use Stage 1 Certification
- Super Doctor
Education
-
University of California Davis -
University of California Davis School of Medicine
Hospital
-
Sutter Auburn Faith Hospital -
University of California, Davis Medical Center
Drug Facts
| NPI NUMBER | 1841272150 | |
| NPPES Provider LastName | VILLABLANCA | |
| NPPES Provider FirstName | AMPARO | |
| NPPES Provider ZIPCode | 958172307 | |
| NPPES Provider State | CA | |
| Specialty Description | Cardiology | |
| Total Claim Count | 1622.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1841272150 |
| Last Name Of The Provider | VILLABLANCA |
| First Name Of The Provider | AMPARO |
| View All |
Similar Doctors
|
|
Dr. Jeffrey M. Paulsen, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. William R. Vetter, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Daniel D. VanHamersveld, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jeffrey A. Southard, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jack W. Casas, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Dali Fan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. William R. Auch, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Richard J. Frink, MD |
|
|
Dr. William R. Lewis, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Thomas W. Smith, MD |
|
|
Dr. Kristi F. Jones, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Satinder Singh, MD |
|
|
Susan E. Robinson, PA
This Doctor is OpenDoctor Recommended.
|
|
|
Gina M. Collier, NP |
|
|
Rebecca Sprague, NPC |
|
|
Dr. Musuvathy S. Jhansi, MD |